Cargando…

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

A 61-year-old woman exhibited right inguinal lymphadenopathy and right lower limb edema approximately 1 month prior to hospitalization. She was diagnosed with high grade B-cell lymphoma, and a lymph node biopsy and fluorescence in situ hybridization indicated MYC, BCL2, and BCL6 rearrangements (trip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitobe, Masaki, Kawamoto, Keisuke, Suzuki, Takaharu, Kiryu, Maiko, Tamura, Suguru, Nanba, Ayako, Suwabe, Tatsuya, Tanaka, Tomoyuki, Fuse, Kyoko, Shibasaki, Yasuhiko, Masuko, Masayoshi, Miyoshi, Hiroaki, Ohshima, Koichi, Sone, Hirohito, Takizawa, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421138/ https://www.ncbi.nlm.nih.gov/pubmed/30210134 http://dx.doi.org/10.2169/internalmedicine.1686-18

Ejemplares similares

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction
por: Mitobe, Masaki, et al.
Publicado: (2021)

Anaplastic large cell lymphoma, with 1,25(OH)((2))D((3))-mediated hypercalcemia: A case report
por: Mitobe, Masaki, et al.
Publicado: (2019)

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma
por: Kawamoto, Keisuke, et al.
Publicado: (2016)

Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review
por: Katagiri, Takayuki, et al.
Publicado: (2017)

Cladribine treatment for Erdheim–Chester disease involving the central nervous system and concomitant polycythemia vera: A case report
por: Tamura, Suguru, et al.
Publicado: (2018)

Genetic manipulation resulting in decreased donor chondroitin sulfate synthesis mitigates hepatic GVHD via suppression of T cell activity
por: Tamura, Suguru, et al.
Publicado: (2023)

Hypertrophic pachymeningitis associated with myelodysplastic syndrome
por: Kaihatsu, Akane, et al.
Publicado: (2020)

Patient‐based prediction algorithm of relapse after allo‐HSCT for acute Leukemia and its usefulness in the decision‐making process using a machine learning approach
por: Fuse, Kyoko, et al.
Publicado: (2019)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan
por: Tsai, Cheng-Chih, et al.
Publicado: (2021)

P1374: EASIX ASSESSED AT 1 YEAR AFTER ALLOGENIC HEMATOPOIETIC CELL TRANSPLANTATION PREDICTS THE ONSET OF SUBSEQUENT NON-RELAPSE MORTALITY
por: Takeda, R., et al.
Publicado: (2022)

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
por: Witte, Hanno M., et al.
Publicado: (2023)

Bcl-B: an “unknown” protein of the Bcl-2 family
por: Pervushin, N. V., et al.
Publicado: (2023)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

TdT Positive Lymphoma with MYC, BCL2 and BCL6 Rearrangements: A Review of Diagnosis and Treatment
por: Singh, Aditi, et al.
Publicado: (2022)

bcl-2-specific siRNAs restore Gemcitabine sensitivity in human pancreatic cancer cells
por: Okamoto, Kinya, et al.
Publicado: (2007)

MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)
por: Takeoka, Kayo, et al.
Publicado: (2022)

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X(L)–Specific Degrader DT2216
por: Thummuri, Dinesh, et al.
Publicado: (2022)

Bcl-2 family member Bcl-G is not a proapoptotic protein
por: Giam, M, et al.
Publicado: (2012)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Yosef, Reut, et al.
Publicado: (2016)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
por: Mo, W., et al.
Publicado: (2022)

Expression of c-Myc, Bcl2, Bcl6, and Cyclin D1 in High-Grade B-Cell Lymphoma
por: Ali, Seemal, et al.
Publicado: (2022)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
por: McPhail, Ellen D., et al.
Publicado: (2018)

Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 Expression
por: Wong, Foong Ying, et al.
Publicado: (2012)

Bcl-XL and Bcl-2 repress a common pathway of cell death
Publicado: (1995)

Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma
por: Mahmoud, Hanan Mohamed, et al.
Publicado: (2011)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Characterization of the signal that directs Bcl-x(L), but not Bcl-2, to the mitochondrial outer membrane
por: Kaufmann, Thomas, et al.
Publicado: (2003)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-2 and Bcl-x(L) Suppress Glucose Signaling in Pancreatic β-Cells
por: Luciani, Dan S., et al.
Publicado: (2013)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

BCL9/BCL9L in hepatocellular carcinoma: Will it or Wnt it be the next therapeutic target?
por: Moghe, Akshata, et al.
Publicado: (2020)

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
por: Peroja, Pekka, et al.
Publicado: (2018)

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing
por: Künstner, Axel, et al.
Publicado: (2021)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6bon239q7v2kdl90mpatoqnmme